Narrow search
Showing 1 - 10 of 1,436
Cover Image
Torasemide: A Pharmacoeconomic Review of its Use in Chronic Heart Failure
Young, Melissa; Plosker, Greg L. - In: PharmacoEconomics 19 (2001) 6, pp. 679-703
double-blind comparative studies against furosemide. Torasemide has been shown to be at least as effective as furosemide in … receiving torasemide had significantly reduced hospital admission rates compared with patients receiving furosemide … $US1944.76 to $US470.76 PPPM) of torasemide treatment. In the furosemide group, average monthly costs for patients …
Persistent link: https://www.econbiz.de/10005590529
Cover Image
Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies
Levy, Emile; Levy, Pierre - In: PharmacoEconomics 20 (2002) 14, pp. 963-977
Over the last two decades the incidence of congestive heart failure (CHF) has increased with aging of the population and in spite of the decline in age-adjusted mortality rates due to coronary heart disease. Its management has seen substantial progress, embodied in the introduction of ACE...
Persistent link: https://www.econbiz.de/10005448970
Cover Image
Specialist Nurse Management Programmes: Economic Benefits in the Management of Heart Failure
Stewart, Simon; Horowitz, John D. - In: PharmacoEconomics 21 (2003) 4, pp. 225-240
Chronic heart failure (CHF) is a modern-day epidemic in most developed countries. As such, it is both common and costly. Contrary to the impression given by clinical trial data, CHF mainly affects older individuals with approximately equal numbers of men and women and concurrent disease profiles...
Persistent link: https://www.econbiz.de/10005449073
Cover Image
Gastrointestinal-Related Healthcare Resource Usage Associated with a Fixed Combination of Diclofenac and Misoprostol versus Other NSAIDs
Rahme, Elham; Joseph, Lawrence; Kong, Sheldon X.; … - In: PharmacoEconomics 19 (2001) 5, pp. 577-588
Objective: To compare gastrointestinal (GI) healthcare resource use (HCRU) and associated costs in patients taking a fixed combination of diclofenac and misoprostol versus other nonsteroidal anti-inflammatory drugs (NSAIDs). Methods: We analysed a sample (49 033 patients) of the Government of...
Persistent link: https://www.econbiz.de/10005590275
Cover Image
Low-Flow Anaesthesia: Does it have Potential Pharmacoeconomic Consequences?
Suttner, Stefan; Boldt, Joachim - In: PharmacoEconomics 17 (2000) 6, pp. 585-590
Healthcare reform has placed increasing pressure on anaesthetists to consider the costs of current anaesthesia strategies. Although the cost of anaesthesia constitutes only a small proportion of total healthcare costs, anaesthetic drug expenditures have been a focus of cost-containment efforts....
Persistent link: https://www.econbiz.de/10005590276
Cover Image
The Economic Costs of Early Stage Prostate Cancer
Saigal, Christopher S.; Litwin, Mark S. - In: PharmacoEconomics 20 (2002) 13, pp. 869-878
The economic costs of early stage prostate cancer are significant, and will likely increase as the proportion of older men grows in the population of industrialised nations. In the US, total costs have been estimated to range from $US1.72 billion to $US4.75 billion annually (1990 costs). Costs...
Persistent link: https://www.econbiz.de/10005590284
Cover Image
Iatrogenic Cost Factors Incorporating Mild and Moderate Adverse Events in the Economic Comparison of Aceclofenac and Other NSAIDs
Peris, Francesc; Martinez, Eduard; Badia, Xavier; Brosa, Max - In: PharmacoEconomics 19 (2001) 7, pp. 779-790
Objective: To perform a modelled economic analysis of the efficacy and tolerability of aceclofenac in comparison with those of other nonsteroidal anti-inflammatory drugs (NSAIDs) used in the treatment of common arthritic disorders including osteoarthritis, rheumatoid arthritis and ankylosing...
Persistent link: https://www.econbiz.de/10005590292
Cover Image
Which Antifungal Agent for Onychomycosis?: A Pharmacoeconomic Analysis
Joish, Vijay N.; Armstrong, Edward P. - In: PharmacoEconomics 19 (2001) 10, pp. 983-1002
The incidence of fungal nail infections is increasing and this is possibly because of several factors: better methods of detection, a growing population of immunocompromised patients who have a greater susceptibility to such infections, the increased use of immunosuppressive drugs, the...
Persistent link: https://www.econbiz.de/10005590302
Cover Image
Influenza: Cost of Illness and Considerations in the Economic Evaluation of New and Emerging Therapies
Cram, Peter; Blitz, Susan G.; Monto, Arnold; Fendrick, … - In: PharmacoEconomics 19 (2001) 3, pp. 223-230
Influenza infection has been a burden to humans for thousands of years. Despite the fact that epidemics could be predicted with regularity, the lack of available prevention or treatment measures left humankind vulnerable to the harmful effects of this ubiquitous virus. While the pandemics of...
Persistent link: https://www.econbiz.de/10005590304
Cover Image
Use of Healthcare Services by Patients Treated with Risperidone Versus Conventional Antipsychotic Agents
Gianfrancesco, Frank; Durkin, Michael B.; Mahmoud, Ramy; … - In: PharmacoEconomics 20 (2002) 6, pp. 413-427
Objective: To determine whether the use of risperidone in a US managed-care environment is associated with a reduction in the use of mental healthcare services. Methods: Mental health service use and costs for patients with psychoses treated with risperidone versus those treated with...
Persistent link: https://www.econbiz.de/10005590323